The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registry

Annelie H. Musters1 | Conor Broderick2 | David Prieto-Merino3 | Andrea Chiricozzi4,5 | Giovanni Damiani6,7,8 | Ketty Peris9,10 | Sandipan Dhar11 | Abhishek De12 | Esther Freeman13,14 | Bernd W. M. Arents15 | Tim Burton16 | Angela Leigh-Ann L. Bosma1 | Ching-Chi Chi17,18 | Godfrey Fletcher19 | Aaron M. Drucker20 | Kenji Kabashima21,22 | Emilie F. de Monchy1 | Maitreyee Panda23 | Dmitri Robert Wall19,24 | Christian Vestergaard25 | Emmanuel Mahe26 | Laura Bonzano27 | Leila Kattach28 | Maddalena Napolitano29 | Maria Fernanda Ordoñez-Rubiano30 | Eva Haufe31 | Cataldo Patruno32 | Alan D. Irvine33 | Phyllis I. Spuls1 | Carsten Flohr2

1Department of Dermatology, Amsterdam UMC, location Academic Medical Center, Amsterdam Public Health Infection and Immunity, University of Amsterdam, Amsterdam, The Netherlands
2Unit for Population-Based Dermatology Research, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London, UK
3Faculty of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, London, UK
4Dermatologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
5Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy
6Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy
7Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
8Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy
9Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy
10OOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli – IRCCS, Rome, Italy
11Department of Pediatric Dermatology, Institute of Child Health, Kolkata, India
12Department of Dermatology, Calcutta National Medical College, Kolkata, India
13Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
14Medical Practice Evaluation Center, Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
15Dutch Association for People with Atopic Dermatitis (VMCE), Nijkerk, The Netherlands
16Patient Representative (independent), Nottingham, UK
17Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
18College of Medicine, Chang Gung University, Taoyuan, Taiwan
19National and International Skin Registry Solutions (NISR), Charles Institute of Dermatology, University College Dublin, Dublin, Ireland
20Department of Medicine, University of Toronto, Toronto, Canada; Women’s College Research Institute, Women’s College Hospital, Toronto, Canada
21Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
22Singapore Immunology Network (SIgN) and Skin Research Institute of Singapore (SRIS), Agency for Science Technology and Research (A*STAR) Biopolis, Singapore, Singapore
23Department of DVL, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India
24Hair Restoration Blackrock, Dublin, Ireland
25Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark

Annelie H. Musters and Conor Broderick authors contributed equally to this manuscript and should be considered joint first authors.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
THE EFFECTS OF SYSTEMIC IMMUNOMODULATORY TREATMENTS ON COVID-19 OUTCOMES IN PATIENTS WITH ATOPIC DERMATITIS: RESULTS FROM THE GLOBAL SECURE-AD REGISTRY

INTRODUCTION

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), causing Coronavirus Disease 2019 (COVID-19), is associated with a highly variable disease course, ranging from asymptomatic infection to severe disease resulting in hospitalization, intensive care unit (ICU) admission, mechanical ventilation and death. Older age, male sex, non-white ethnicity, obesity, diabetes and underlying immunosuppression are important factors associated with a more severe clinical course. 

Background: Limited data are available on the effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis (AD).

Objective: To investigate COVID-19 outcomes in patients with AD treated with or without systemic immunomodulatory treatments, using a global registry platform.

Methods: Clinicians were encouraged to report cases of COVID-19 in their patients with AD in the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Atopic Dermatitis (SECURE-AD) registry. Data entered from 1 April 2020 to 31 October 2021 were analysed using multivariable logistic regression. The primary outcome was hospitalization from COVID-19, according to AD treatment groups.

Results: 442 AD patients (mean age 35.9 years, 51.8% male) from 27 countries with strongly suspected or confirmed COVID-19 were included in analyses. 428 (96.8%) patients were treated with a single systemic therapy (n = 297 [67.2%]) or topical therapy only (n = 131 [29.6%]). Most patients treated with systemic therapies received dupilumab (n = 216). Fourteen patients (3.2%) received a combination of systemic therapies. Twenty-six patients (5.9%) were hospitalized. No deaths were reported. Patients treated with topical treatments had significantly higher odds of hospitalization, compared with those treated with dupilumab monotherapy (odds ratio (OR) 4.65 [95%CI 1.71–14.78]), including after adjustment for confounding variables (adjusted OR (aOR) 4.99 [95%CI 1.4–20.84]). Combination systemic therapy which did not include systemic corticosteroids was associated with increased odds of hospitalization, compared with single agent non-steroidal immunosuppressive systemic treatment (OR 8.09 [95%CI 0.4–59.96], aOR 37.57 [95%CI 1.05–871.11]). Hospitalization was most likely in patients treated with combination systemic therapy which included systemic corticosteroids (OR 40.43 [95%CI 8.16–207.49], aOR 45.75 [95%CI 4.54–616.22]).

Conclusions: Overall, the risk of COVID-19 complications appears low in patients with AD, even when treated with systemic immunomodulatory agents. Dupilumab monotherapy was associated with lower hospitalization than other therapies. Combination systemic treatment, particularly combinations including systemic corticosteroids, was associated with the highest risk of severe COVID-19.
Atopic dermatitis (AD, also known as atopic eczema) is a complex chronic inflammatory skin disease. Both genetic and environmental factors play a role in AD pathogenesis. AD is characterized by skin barrier dysfunction and altered cell-mediated immunity. Compared with the general population, cutaneous and systemic infections are more common in patients with AD; therefore, it is plausible that SARS-CoV-2 infection, as well as the risks associated with COVID-19, could be affected by intrinsic immune dysregulation in AD.

A recent epidemiological study using electronic healthcare records demonstrated that many inflammatory skin diseases, including AD, acne, psoriasis and cutaneous lupus, were associated with higher risk of COVID-19, even after controlling for age, gender, ethnicity, obesity and deprivation status. However, patients with these inflammatory skin diseases had an overall lower odds of mechanical ventilation.

Patients with moderate-to-severe AD are often treated with systemic immunomodulatory therapy, including systemic corticosteroids and conventional systemic therapies, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil. More recently, biologics such as dupilumab and tralokinumab, and small immunomodulatory molecules including the Janus Kinase inhibitors (JAKi) baricitinib, up-adactinib and abrocitinib, have been approved in several countries for the treatment of AD. Clinicians and patients must consider the potentially increased risk of infection associated with immunomodulatory treatments, especially in the context of a global pandemic, as differing mechanisms of action and levels of immunosuppression may impart variable risks of serious infections. Contrastingly, some degree of immunomodulation may have beneficial effects on the rate of SARS-CoV-2 infection, and targeting of specific immune pathways could reduce the development of a hyper-inflammatory state in severe COVID-19, a hypothesis supported by the recent World Health Organization recommendation for using baricitinib in the treatment of severe or critical COVID-19.

Responding to the urgent need to better understand the determinants of COVID-19 outcomes and whether immunomodulatory treatments for AD affect the risk of morbidity and mortality, the SECURE-AD (Surveillance Epidemiology of Coronavirus (COVID-19) Under Research Exclusion – Atopic Dermatitis) Physician Registry was launched in April 2020. The primary aim of the SECURE-AD study was to evaluate the effects that different systemic immunomodulatory AD treatments have on COVID-19 outcomes.

**METHODS**

**Study design, setting and patients**

The SECURE-AD Physician Registry is a global web-based registry, launched through international collaboration between clinicians, researchers and patients with AD (https://www.covidderm.org/). The study was promoted by national and international dermatology and patient partner organizations (see Acknowledgements). Clinicians were encouraged to report all cases of COVID-19 in patients with AD, and were required to register using their name, email and hospital affiliation. Ethical approval was granted by the Leeds Research Ethics Committee (20/YH/0135) and by the Irish National Research Committee for COVID-19-related Health Research (NREC COVID-19).

AD patients of all ages and any AD severity with suspected or confirmed COVID-19 (including asymptomatic patients detected through public health screening) were eligible for inclusion. Clinicians were asked to allow sufficient time to pass to observe disease progression, experience partial or complete recovery, hospitalization or death. Patients with AD taking immunomodulatory medication for an indication other than AD were excluded.

**Data collection and outcomes**

Anonymized observational data were collected using a web-based case report form (CRF), hosted on the OpenAppIT Clinical Insight platform (Dublin, Ireland). A single CRF was completed for each patient which included demographics (age, sex, ethnicity, country of residence), patient characteristics (body mass index [BMI], smoking status, comorbidities, concomitant medications), date of diagnosis and AD disease activity (prior to and during COVID-19), and details of AD treatments. Although additional ethnicity options were pre-specified, ethnicity data were condensed (White, South Asian, Other, Unknown) for the regression analysis due to sample sizes.

Clinicians reported COVID-19 disease course and outcomes (duration of symptoms, persistence of COVID-19 symptoms at the time of reporting, death due to COVID-19, Emergency Department (ED) attendance, hospitalization, length of hospital stay, intensive care unit (ICU) admission, ventilation requirement, and flare (exacerbation) of AD during COVID-19). Hospitalization due to COVID-19 was selected as the primary measure of severe COVID-19 in our cohort due to low numbers of reported ICU admissions or mechanical ventilation. The web-based CRF was not altered since it was launched on 1 April 2020, so data on COVID-19 vaccination status were not collected.

CRFs were carefully designed to avoid traceability and only anonymized data were submitted to SECURE-AD. In line with the Declaration of Helsinki (1975, revised 2013), written consent from patients was not required. All data were collected and processed exclusively for the promotion of scientific and medical research, carried out in the public interest.

Data collection was harmonized with concurrent efforts studying other immune-mediated inflammatory diseases (IMIDs), for example, SECURE-Alopecia, SECURE-IBD, PsoProtect and the Global Rheumatology Alliance.
Statistical analysis

Based on data availability, drug class and mechanisms of action, we created immunomodulatory treatment groups. We summarized demographics and clinical characteristics and COVID-19 outcomes of the study population using descriptive statistics.

To minimize the risk of over-fitting logistic regression models for hospitalization by including each comorbidity as an individual variable, we created a cohort-specific “comorbidity score,” using each patient’s comorbidities and Body Mass Index (BMI). Presence or absence of comorbidities (asthma, other lung diseases including COPD, cardiovascular disease, hypertension, diabetes and stroke) and BMI were used to model the risk of hospitalization from COVID-19. This model gives a higher coefficient to the comorbidities that better predict hospitalization (irrespective of AD treatments) and these coefficients are used as the weights in our comorbidity score.

We report two main analyses to evaluate the effects of immunomodulatory therapies on COVID-19 outcomes. Firstly, to evaluate the effects of individual systemic treatments, patients receiving topical therapy only or a single systemic therapy for AD (i.e. systemic monotherapy) were analysed separately to those receiving systemic therapies in combination. Treatment groups in the monotherapy analysis were as follows: topical treatment only, dupilumab, methotrexate, ciclosporin, systemic corticosteroids, other conventional immuno-suppressant treatments (azathioprine and mycophenolate mofetil), JAKi and other systemic treatments (including tralokinumab and other biologic and small molecule treatments [omalizumab and apremilast]). 95% confidence intervals (95%CI) associated with percentages experiencing COVID-19 outcomes were calculated by Pearson–Klopper method, using R’s binom package v1.1-1.25 Logistic regression was used to generate odds ratios (OR) and 95%CI for hospitalization according to immunomodulatory treatment groups, using dupilumab monotherapy as the reference group. Regression models were then adjusted for age, sex, ethnicity and each patient’s comorbidity score.

Secondly, we evaluated the effect of systemic therapies used in combination, stratified according to whether the combination included systemic corticosteroids. The following systemic treatment groups were created: any non-steroidal immunosuppressive systemic treatment (NSISS) as monotherapy (reference group), systemic corticosteroids as monotherapy, combination treatment not including systemic corticosteroids, and combination treatment including systemic corticosteroids. Patients receiving topical therapies only were excluded from the combination treatment analysis. Adjusted OR (aOR) and 95%CI for hospitalization due to COVID-19 were calculated, adjusted as per the monotherapy analysis.

Patients reported in the registry from 1 April 2020 to 31 October 2021 were included in this analysis. All analyses were performed using R (Vienna, Austria), version 4.1.1. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement for cross-sectional studies was used.26

RESULTS

452 patients with AD and a COVID-19 diagnosis from 27 countries were registered in the SECURE-AD Physician Registry. Ten patients were excluded from further analysis: 3 receiving systemic immunomodulation for conditions other than AD, 3 participating in blinded clinical trials and 4 who had an unknown COVID-19 outcome. One patient receiving tofacitinib for rheumatoid arthritis, in combination with dupilumab, was retained in the analysis due to presumed similar mechanism of action of JAKi used in AD.

Demographics, clinical characteristics and COVID-19 outcomes

Table 1 provides a summary of demographics and clinical characteristics of the study subjects (n = 442), as well as full details of AD therapies used and the observed variation between immunomodulatory treatment groups. All combinations of systemic immunomodulatory treatments are summarized together in Table 1, and the number of patients receiving each specific combination of treatments is listed in the accompanying footnote. Further details of the doses of systemic treatments used are available in Table S1 (single agent systemic therapy, i.e. systemic monotherapy) and Table S2 (systemic treatments used in combination). Table 2 outlines the overall proportions of patients with pre-defined COVID-19 outcomes. Hospitalization was reported in 26 patients (5.9%). ICU admissions (n = 8, 1.8%) and mechanical ventilation were infrequent (n = 6, 1.4%) and there were no reported deaths.

COVID-19 outcomes in patients treated with topical or single agent systemic immunomodulatory therapy (monotherapy analysis)

Figure 1 depicts the proportions of patients with pre-specified COVID-19 outcomes, according to their immunomodulatory treatment group. Forty-eight patients in the monotherapy analysis attended the Emergency Department (ED). ED attendance rates differed between treatment groups (p = 0.053) and was higher in those treated with topical treatments compared to dupilumab (15.5% vs 8.7%, p = 0.075). Overall, hospitalization because of COVID-19 was infrequent (n = 21 [5.2%]), but the proportions of hospitalized patients varied between the treatment groups (p = 0.068) and was highest in those treated with systemic corticosteroids (14.3%). Patients treated with topical treatments were more likely to be hospitalized than those treated with dupilumab (9.9% vs 2.3%, p = 0.004). Compared with dupilumab
| TABLE 1  Demographics and clinical characteristics |
|---------------------------------------------------|
| **COVID-19 cases** | Overall | Topical treatments only | Dupilumab | Methotrexate | Ciclosporin | Systemic corticosteroids | Other conventional immuno-suppressants | JAK inhibitors | Other biologic/small molecule treatments | Combination treatments | *p*-value |
| COVID-19 cases | 442 | 131 | 216 | 30 | 22 | 7 | 6 | 12 | 4 | 14 | 0.661 |
| **Sex (%)** | | | | | | | | | | | | <0.001 |
| Female | 213 (48.2) | 58 (44.3) | 108 (50.0) | 15 (50.0) | 8 (36.4) | 3 (42.9) | 5 (83.3) | 6 (50.0) | 2 (50.0) | 8 (35.7) | 2 (25.0) |
| Male | 229 (51.8) | 73 (55.7) | 108 (50.0) | 15 (50.0) | 14 (63.6) | 4 (57.1) | 1 (16.7) | 6 (50.0) | 2 (50.0) | 6 (42.9) | 6 (25.0) |
| **Age, mean (SD)** | 35.93 (18.00) | 28.58 (18.10) | 40.38 (16.92) | 38.73 (19.78) | 29.95 (13.15) | 63.43 (18.31) | 30.00 (9.94) | 37.00 (22.79) | 40.75 (17.80) | 41.64 (15.79) | <0.001 |
| **Age category (%)** | | | | | | | | | | | | <0.001 |
| <2 years | 5 (1.1) | 5 (3.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 2–9 years | 20 (4.5) | 17 (13.0) | 1 (0.5) | 0 (0.0) | 0 (0.0) | 2 (9.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 10–19 years | 60 (13.6) | 24 (18.3) | 19 (8.8) | 7 (23.3) | 2 (9.1) | 1 (14.3) | 2 (25.0) | 1 (25.0) | 1 (25.0) | 4 (33.3) | 2 (14.3) |
| 20–39 years | 168 (38.0) | 47 (35.9) | 86 (39.8) | 10 (33.3) | 12 (54.5) | 4 (57.1) | 4 (66.7) | 3 (25.0) | 0 (0.0) | 2 (14.3) | 2 (14.3) |
| 40–59 years | 145 (32.8) | 32 (24.4) | 79 (36.6) | 9 (30.0) | 6 (27.3) | 1 (14.3) | 1 (16.7) | 5 (41.7) | 3 (75.0) | 9 (64.3) | 9 (64.3) |
| 60–79 years | 40 (9.0) | 6 (4.6) | 30 (13.9) | 2 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (8.3) | 0 (0.0) | 1 (7.1) |
| ≥80 years | 4 (0.9) | 0 (0.0) | 1 (0.5) | 2 (6.7) | 0 (0.0) | 1 (14.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Ethnicity (%)** | | | | | | | | | | | | <0.001 |
| White | 286 (64.7) | 54 (41.2) | 175 (81.0) | 17 (56.7) | 11 (50.0) | 2 (28.6) | 3 (50.0) | 9 (75.0) | 3 (75.0) | 12 (85.7) | 12 (85.7) |
| South Asian | 60 (13.6) | 36 (27.5) | 8 (3.7) | 5 (16.7) | 7 (31.8) | 2 (28.6) | 0 (0.0) | 1 (8.3) | 1 (25.0) | 0 (0.0) | 0 (0.0) |
| Asian–Chinese | 2 (0.5) | 1 (0.8) | 1 (0.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Asian–other | 4 (0.9) | 4 (3.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Hispanic or Latino | 14 (3.2) | 4 (3.1) | 4 (1.9) | 1 (3.3) | 1 (4.5) | 1 (14.3) | 1 (16.7) | 1 (8.3) | 0 (0.0) | 1 (7.1) | 1 (7.1) |
| Afro Caribbean | 8 (1.8) | 2 (1.5) | 5 (2.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Black African | 5 (1.1) | 2 (1.5) | 3 (1.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Other | 6 (1.4) | 2 (1.5) | 0 (0.0) | 2 (6.7) | 0 (0.0) | 0 (0.0) | 1 (16.7) | 1 (8.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Unknown | 57 (12.9) | 26 (19.8) | 20 (9.3) | 5 (16.7) | 3 (13.6) | 2 (28.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (7.1) | 1 (7.1) |
| **Country of residence (%)** | | | | | | | | | | | | <0.001 |
| Italy | 138 (31.2) | 9 (6.9) | 112 (51.9) | 1 (3.3) | 4 (18.2) | 2 (28.6) | 0 (0.0) | 3 (25.0) | 2 (50.0) | 5 (35.7) | 5 (35.7) |
| India | 64 (14.5) | 41 (31.3) | 2 (0.9) | 8 (26.7) | 10 (45.5) | 2 (28.6) | 0 (0.0) | 0 (0.0) | 1 (25.0) | 0 (0.0) | 0 (0.0) |
| United Kingdom | 61 (13.8) | 7 (5.3) | 26 (12.0) | 13 (43.3) | 2 (9.1) | 0 (0.0) | 2 (33.3) | 4 (33.3) | 1 (25.0) | 6 (42.9) | 6 (42.9) |
| France | 36 (8.1) | 17 (13.0) | 16 (7.4) | 2 (6.7) | 0 (0.0) | 0 (0.0) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |

(Continues)
### Table 1 (Continued)

| Overall                  | Topical treatments only | Dupilumab | Methotrexate | Ciclosporin | Systemic corticosteroids | Other conventional immuno-suppressants | JAK inhibitors | Other biologic/small molecule treatments | Combination treatments | \( p \)-value |
|--------------------------|-------------------------|-----------|--------------|-------------|--------------------------|----------------------------------------|-----------------|------------------------------------------|------------------------|--------------|
| The Netherlands          | 31 (7.0)                | 7 (5.3)   | 21 (9.7)     | 1 (3.3)     | 1 (4.5)                  | 0 (0.0)                               | 0 (0.0)        | 1 (8.3)                                  | 0 (0.0)                | 0 (0.0)      |
| United States            | 20 (4.5)                | 14 (10.7) | 3 (1.4)      | 0 (0.0)     | 0 (0.0)                  | 0 (0.0)                               | 0 (0.0)        | 2 (16.7)                                 | 0 (0.0)                | 1 (7.1)      |
| Europe (other)           | 61 (13.8)               | 20 (15.3) | 26 (12.0)    | 4 (13.3)    | 4 (18.2)                 | 2 (28.6)                              | 2 (33.3)       | 2 (16.7)                                 | 0 (0.0)                | 1 (7.1)      |
| South America            | 16 (3.6)                | 5 (3.8)   | 6 (2.8)      | 1 (3.3)     | 1 (4.5)                  | 1 (14.3)                              | 1 (16.7)       | 0 (0.0)                                  | 0 (0.0)                | 1 (7.1)      |
| Asia (other)             | 9 (2.0)                 | 9 (6.9)   | 0 (0.0)      | 0 (0.0)     | 0 (0.0)                  | 0 (0.0)                               | 0 (0.0)        | 0 (0.0)                                  | 0 (0.0)                | 0 (0.0)      |
| Middle East              | 4 (0.9)                 | 0 (0.0)   | 4 (1.9)      | 0 (0.0)     | 0 (0.0)                  | 0 (0.0)                               | 0 (0.0)        | 0 (0.0)                                  | 0 (0.0)                | 0 (0.0)      |
| North America (other)    | 2 (0.5)                 | 2 (1.5)   | 0 (0.0)      | 0 (0.0)     | 0 (0.0)                  | 0 (0.0)                               | 0 (0.0)        | 0 (0.0)                                  | 0 (0.0)                | 0 (0.0)      |

| Dose of systemic treatment, median (IQR) | See Table S1 | 12.5 mg (10–15 mg) per week\(^a\) | See Table S1 | 100 mg (100–150 mg) per day\(^b\) | See Table S1 | See Table S1 | See Table S1 | See Table S1 | See Table S2 |
|----------------------------------------|--------------|-----------------------------------|--------------|-------------------------------|--------------|--------------|--------------|--------------|--------------|
| Dose by weight, median (IQR)           | NA           | NA                                | 0.18 mg/kg (0.16–0.23 mg/kg) per week\(^a\) | NA            | 2.86 mg/kg (2.22–3.15 mg/kg) per day\(^b\) | NA           | NA           | NA           | NA           | NA          |

**Method of COVID-19 diagnosis (%)**

| Positive test             | 305 (69.0) | 103 (78.6) | 137 (63.4) | 20 (66.7) | 20 (90.9) | 5 (71.4) | 4 (66.7) | 4 (33.3) | 3 (75.0) | 9 (64.3) | 0.008       |
| Presumptive diagnosis based on typical features | 135 (30.5) | 28 (21.4) | 77 (35.6) | 10 (33.3) | 2 (9.1) | 2 (28.6) | 2 (33.3) | 8 (66.7) | 1 (25.0) | 5 (35.7) | 0.239       |
| Unknown                   | 2 (0.5)    | 0 (0.0)   | 2 (0.9)   | 0 (0.0)   | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.059       |
| BMI (median (IQR)) – patients aged 16+ only | 24.05 (21.92, 26.51) | 23.15 (21.63, 25.31) | 24.54 (22.22, 26.83) | 23.84 (22.04, 26.47) | 22.49 (21.08, 24.24) | 23.77 (21.32, 26.07) | 25.44 (23.83, 29.26) | 22.95 (21.71, 24.98) | 24.73 (22.74, 27.57) | 25.97 (23.51, 31.20) | 0.239       |

**BMI categories (%) – patients aged 16+ only**

| BMI <19 | 11 (2.8) | 2 (2.2) | 7 (3.4) | 0 (0.0) | 1 (5.3) | 0 (0.0) | 0 (0.0) | 1 (8.3) | 0 (0.0) | 0 (0.0) | 0.059       |

\(^a\) \(^b\) See Table S1 and Table S2.
**TABLE 1** (Continued)

| Comorbidities (%) | Overall | Topical treatments only | Dupilumab | Methotrexate | Ciclosporin | Systemic corticosteroids | Other conventional immunosuppressants | JAK inhibitors | Other biologic/small molecule treatments | Combination treatments | p-value |
|-------------------|---------|-------------------------|-----------|--------------|-------------|--------------------------|---------------------------------------|----------------|------------------------------------------|----------------------|---------|
| **BMI 19–25**     | 206 (53.4) | 54 (58.7) | 104 (50.0) | 15 (55.6) | 12 (63.2) | 3 (50.0) | 2 (40.0) | 8 (66.7) | 2 (50.0) | 6 (46.2) | <0.001 |
| **BMI 25–30**     | 100 (25.9) | 17 (18.5) | 64 (30.8) | 6 (22.2) | 4 (21.1) | 3 (50.0) | 1 (20.0) | 2 (16.7) | 1 (25.0) | 2 (15.4) | <0.001 |
| **BMI > 30**      | 38 (9.8) | 4 (4.3) | 22 (10.6) | 4 (14.8) | 0 (0.0) | 0 (0.0) | 1 (20.0) | 1 (8.3) | 1 (25.0) | 5 (38.5) | 0.39   |
| Unknown           | 31 (8.0) | 15 (16.3) | 11 (5.3) | 2 (7.4) | 2 (10.5) | 0 (0.0) | 1 (20.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |        |

**AD activity prior to COVID-19 infection (%)**

| Remission         | 211 (47.7) | 38 (29.0) | 63 (29.2) | 6 (20.0) | 1 (4.5) | 1 (14.3) | 2 (33.3) | 5 (41.7) | 1 (25.0) | 1 (7.1) | <0.001 |
| Mild              | 76 (17.2) | 62 (47.3) | 113 (52.3) | 10 (33.3) | 5 (22.7) | 1 (14.3) | 4 (66.7) | 6 (50.0) | 3 (75.0) | 7 (50.0) |        |
| Moderate          | 118 (26.7) | 20 (15.3) | 25 (11.6) | 13 (43.3) | 11 (50.0) | 5 (71.4) | 0 (0.0) | 1 (8.3) | 0 (0.0) | 1 (7.1) |        |
| Severe            | 29 (6.6) | 7 (5.3) | 11 (5.1) | 1 (3.3) | 5 (22.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (35.7) |        |
| Unknown           | 8 (1.8) | 4 (3.1) | 4 (1.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |        |

**Comorbidities (%)**

| Asthma            | 143 (32.4) | 35 (26.7) | 71 (32.9) | 11 (36.7) | 8 (36.4) | 3 (42.9) | 1 (16.7) | 5 (41.7) | 3 (75.0) | 6 (42.9) | 0.446 |
| COPD or other lung disease | 14 (3.2) | 5 (3.8) | 6 (2.8) | 2 (6.7) | 0 (0.0) | 1 (14.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.624 |
| Allergic rhinitis | 52 (11.8) | 3 (2.3) | 37 (17.1) | 4 (13.3) | 1 (4.5) | 1 (14.3) | 1 (16.7) | 1 (8.3) | 1 (25.0) | 3 (21.4) | 0.008 |
| Cardiovascular disease | 19 (4.3) | 3 (2.3) | 11 (5.1) | 2 (6.7) | 0 (0.0) | 0 (0.0) | 1 (16.7) | 1 (8.3) | 0 (0.0) | 1 (7.1) | 0.593 |
| Hypertension      | 40 (9.0) | 9 (6.9) | 25 (11.6) | 3 (10.0) | 0 (0.0) | 0 (0.0) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 2 (14.3) | 0.45   |
| Stroke            | 4 (0.9) | 0 (0.0) | 4 (1.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.836 |
| Diabetes          | 22 (5.0) | 8 (6.1) | 11 (5.1) | 0 (0.0) | 1 (4.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (14.3) | 0.645 |
| Chronic liver disease | 7 (1.6) | 3 (2.3) | 2 (0.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (14.3) | 0.32   |
| Chronic kidney disease | 5 (1.1) | 1 (0.8) | 4 (1.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.972 |
| Cancer            | 2 (0.5) | 0 (0.0) | 1 (0.5) | 1 (3.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.6    |
| Other             | 66 (14.9) | 8 (6.1) | 44 (20.4) | 5 (16.7) | 0 (0.0) | 1 (14.3) | 2 (33.3) | 0 (0.0) | 0 (0.0) | 6 (42.9) | <0.001 |
| None              | 174 (39.4) | 77 (58.8) | 62 (28.7) | 12 (40.0) | 12 (54.5) | 2 (28.6) | 1 (16.7) | 6 (50.0) | 0 (0.0) | 2 (14.3) | <0.001 |

**Smoking status (%)**

| Current smoker | 63 (14.3) | 15 (11.5) | 39 (18.1) | 2 (6.7) | 0 (0.0) | 2 (16.7) | 1 (25.0) | 1 (7.1) |        |        | 0.39   |

(Continues)
(14.9%), patients treated with topical treatments (34.4%), ciclosporin (31.8%) and JAKi (36.4%) were more likely to experience a flare (exacerbation) of AD during COVID-19 ($p < 0.001$, $p = 0.065$, $p = 0.08$ respectively). Table S3 presents the $p$-values for between group comparisons for each pre-specified COVID-19 outcome.

### Regression analysis of hospitalization rates according to topical or single agent systemic immunomodulatory treatment group

To further explore the differences in hospitalization rates observed between systemic treatments identified in the monotherapy analysis (Figure 1, Table S3), a multivariable logistic regression model was fitted, adjusting for confounding variables (age, sex, ethnicity, comorbidity score). No hospitalizations were reported in patients treated with JAKi ($n = 12$), other conventional immuno-suppressant treatments ($n = 6$), or other biologic/small molecule treatments ($n = 4$), so these treatment groups were excluded from regression analysis. An additional 41 patients with missing BMI data were excluded, leaving 365 patients to assess the association between hospitalization and topical treatments and systemic monotherapy (Figure 2). Compared with patients prescribed dupilumab, patients treated with topical treatments had significantly higher rates of hospitalization from COVID-19 (OR 4.65 [95%CI 1.71–14.78]), including after adjusting for age, sex, ethnicity and comorbidity score (aOR 4.99 [95%CI 1.4–20.84]). Compared with dupilumab, hospitalization was more frequently reported in patients receiving systemic corticosteroids (OR 7.03 [95%CI 0.34–53.86], aOR 2.85 [95%CI 0.08–38.11]), or ciclosporin (OR 2.01 [95%CI 0.1–13.25], aOR 3.02 [95%CI 0.14–25.72]); however, these findings were not statistically significant. After adjustment for confounding variables, patients treated with methotrexate and dupilumab had equivalent odds of hospitalization (OR 1.46 [95%CI 0.07–9.45], aOR 0.98 [95%CI 0.05–7.58]).

### Exploring the effects of combination systemic therapy on COVID-19 outcomes in patients with AD (combination treatment analysis)

To evaluate the effects of systemic treatments used in combination, a subgroup analysis including patients treated with systemic monotherapy ($n = 297$) or combination systemic therapy ($n = 14$) was performed. Patients were prescribed systemic corticosteroids as monotherapy ($n = 7$), NSISS as monotherapy ($n = 290$), combination treatments not including systemic corticosteroids ($n = 6$) and combination treatments including systemic corticosteroids ($n = 8$). Figure 3 depicts the proportions of patients in each treatment group with each pre-specified COVID-19 outcome. Patients prescribed combination treatments including systemic corticosteroids had the highest rates of
| TABLE 2 COVID-19 outcomes |
|---------------------------|
|                           |
| **Cases of COVID-19**     |
| Overall                   | 442 |
| Topical treatments only   | 131 |
| Dupilumab                 | 216 |
| Methotrexate              | 30  |
| Ciclosporin               | 22  |
| Systemic corticosteroids  | 7   |
| Other conventional immuno-suppressants | 6 |
| JAK inhibitors            | 12  |
| Other biologic/small molecule treatments | 4 |
| Combination treatments    | 14  |
| **Duration of COVID-19 symptoms in days (median [IQR])** |
| Overall                   | 7.0 (3.0, 14.0) |
| Topical treatments only   | 6.0 (0.0, 11.0) |
| Dupilumab                 | 7.0 (4.0, 14.0) |
| Methotrexate              | 10.0 (3.0, 15.5) |
| Ciclosporin               | 12.0 (6.0, 15.0) |
| Systemic corticosteroids  | 14.0 (3.0, 14.0) |
| Other conventional immuno-suppressants | 6.0 (5.0, 24.25) |
| JAK inhibitors            | 8.0 (7.0, 13.0) |
| Other biologic/small molecule treatments | 10.0 (8.25, 11.75) |
| Combination treatments    | 19.0 (11.0, 42.0) |
| **Complete resolution of COVID-19 (%)** |
| Yes                       | 302 (68.3) |
| No                        | 34 (7.7) |
| Unknown                   | 106 (24.0) |
| **ED attendance (%)**     |
| Yes                       | 55 (12.4) |
| No                        | 373 (84.4) |
| Unknown                   | 14 (3.2) |
| **Hospitalized (%)**      |
| Yes                       | 18 (8.3) |
| No                        | 189 (87.5) |
| Unknown                   | 9 (4.2) |
| **Median length of hospital stay in days (IQR)** |
| Yes                       | 8.0 (4.0, 11.0) |
| No                        | 6.0 (4.0, 10.0) |
| Unknown                   | 11.0 (9.0, 12.0) |
| **Admitted to ICU (%)**   |
| Yes                       | 8 (1.8) |
| No                        | 3 (2.3) |
| Unknown                   | 2 (0.9) |
| **Required ventilation (%)** |
| Yes                       | 6 (1.4) |
| No                        | 3 (1.4) |
| Unknown                   | 0 (0.0) |
| **AD flare during COVID-19 (%)** |
| Yes                       | 100 (22.6) |
| No                        | 317 (71.7) |
| Unknown                   | 25 (5.7) |

Note: The category ‘other conventional immuno-suppressants’ includes patients on azathioprine (n = 4), and mycophenolate mofetil (n = 2). The category ‘JAK inhibitors’ includes patients on upadacitinib (n = 7), abrocitinib (n = 4), and an unspecified JAK inhibitor (n = 1). The category ‘other biologic/small molecule treatment’ includes patients on omalizumab (n = 2), tralokumab (n = 1), and apremilast (n = 1). The category ‘combination treatments’ includes patients on dupilumab + systemic corticosteroids (n = 6), dupilumab + ciclosporin (n = 2), dupilumab + methotrexate (n = 1), dupilumab + tofacitinib (n = 1), azathioprine + systemic corticosteroids (n = 1), ciclosporin + systemic corticosteroids (n = 1), ciclosporin + methotrexate (n = 1), and mycophenolate mofetil + omalizumab (n = 1). Median length of stay calculated among hospitalized patients only.
ED attendance, hospitalization, ICU admission, ventilation, AD flares (exacerbations) and persistent COVID-19 symptoms. Statistically significant comparisons between treatment groups are highlighted in Figure 3, and p-values for all comparisons are presented in Table S4. The effects of combination systemic therapy on hospitalization from COVID-19 were investigated further using multivariable logistic regression, adjusted for confounding variables (age, sex, ethnicity, comorbidity score [Figure 4]). Compared with patients treated with any NSISS as monotherapy, significantly higher rates of hospitalization from COVID-19 were reported in patients treated with combination therapy including systemic corticosteroids (OR 40.43 [95%CI 8.16–207.49], aOR 45.75 [95%CI 4.54–616.22]), and in patients treated with combination therapy not including systemic corticosteroids (OR 8.09 [95%CI 0.4–59.96], aOR 37.57 [95%CI 1.05–871.11]). Compared with single agent NSISS, systemic corticosteroid monotherapy was associated with

| Outcome                          | p-value | Median (IQR) |
|----------------------------------|---------|--------------|
| Emergency Department attendance  | 0.053   | 15.5% (7.7%) |
| Hospitalization                  | 0.068   | 9.9% (2.3%)  |
| ICU admission                    | 0.781   | 2.3% (0.9%)  |
| Ventilation                      | 0.624   | 0% (0%)      |
| AD flares during COVID-19        | 0.002   | 34.4% (14.9%)|
| Persistent COVID-19 symptoms     | 0.445   | 8.2% (14.3%)|

**Figure 1** Barchart demonstrating the proportions of patients and their pre-specified COVID-19 outcomes, according to the immunomodulatory treatment groups. Patients receiving topical therapy (n = 131) or a single systemic therapy for atopic dermatitis (n = 297) were included. 95% confidence intervals around the percentage of each outcome were calculated using the Pearson–Klopper method. p-values were calculated using Fisher’s exact test for differences across all groups (boxed p-values). Asterix notation shows statistically significant differences between bracketed pairs of treatments (p-values > 0.1 are not shown but are available in Table S3). AD, atopic dermatitis; ICU, intensive care unit; JAK inhibitor, Janus kinase inhibitor.
higher rates of hospitalization (OR 6.74 [95%CI 0.33–47.64], aOR 1.87 [95%CI 0.03–55.4]), although the difference was not statistically significant.

DISCUSSION

In this global registry study of AD patients from 27 countries, we found important differences in COVID-19 outcomes between different treatment modalities, even if hospitalization rates overall (5.9% of all SECURE-AD patients) did not appear higher than would be expected in the general population. Compared with other IMID registries, hospitalization rates in SECURE-AD patients were lower than reported in patients with inflammatory bowel disease (IBD, 31%), rheumatic diseases (46%) or psoriasis (21%). Fatality rates were also higher in the comparable studies (3%, 10.5% and 2%, respectively, vs 0% in the SECURE-AD physician registry).

Among patient treated with systemic monotherapy, the highest rates of hospitalization were seen in those receiving systemic corticosteroids (14.3%). This finding is consistent with results reported for patients with rheumatic diseases, where ≥10 mg prednisolone/day (or equivalent) was associated with higher COVID-19-related mortality, compared with patients prescribed methotrexate.

Compared with dupilumab, topical treatments were associated with significantly higher rates of hospitalization from COVID-19, even after adjusting for confounding variables (aOR 4.99 [95%CI 1.4–20.84]). Compared with dupilumab, patients on methotrexate had equivalent odds of hospitalization, and dupilumab was associated with lower odds of hospitalization than ciclosporin, or systemic corticosteroids, although these findings did not reach statistical significance.

Dupilumab targets interleukin (IL)-4 and IL-13 which are not activated for viral infections; therefore, inhibition is not expected to significantly affect rates of SARS-CoV-2 infection. COVID-19 is characterized by an exaggerated Th1/Th17 immune response and can be associated with a cytokine storm in severe disease. Emerging evidence suggests that expression of Th2 cytokines, including IL-4 and IL-13, may also be increased during COVID-19. Our data reinforces the established safety profile of dupilumab from clinical trials and case series during the COVID-19 pandemic. In an electronic health record analysis, dupilumab exposure (for any indication) was associated with a lower risk of ventilation and death from COVID-19 (risk of death in dupilumab-treated cohort: 0% vs 1.98% in those not receiving dupilumab [95%CI 1.94–2.03%]). Using the COVID-19 Research Database, Wu et al. compared the risk of contracting SARS-CoV-2 in patients prescribed different AD treatments. Patients on dupilumab were at lower risk of infection, compared to patients on prednisone, ciclosporin, azathioprine and patients not on systemic medication. In contrast to our work, this study did not examine the severity of COVID-19 in relation to AD treatments. Ungar et al. reported a prospective, single-centre case series of patients with moderate–severe AD (n = 1237), of whom 87 experienced a COVID-19 episode, and reported no deaths or ICU admissions, and only 4 hospitalizations due to COVID-19. In contrast to our study, which used hospitalization as the primary outcome of severe COVID-19, Ungar et al. created a custom COVID-19 symptom severity score and found that patients treated with dupilumab experienced fewer and less severe COVID-19 symptoms, compared with patients on other systemic treatments, phototherapy, and topical or no treatments. While their study provides useful insights into COVID-19 symptoms in patients with AD treated with systemic therapies, the generalizability of this study’s findings is limited by low rates of laboratory-confirmed COVID-19 (7%, compared with 69% in our study) and the use of a COVID-19 symptom score, rather than more objective measures of COVID-19 severity, such as hospitalization or ICU admission.

Our subgroup analysis including patients treated with either a single systemic agent or combination systemic therapy showed that patients treated with combination therapy including systemic corticosteroids had the highest rates of ED attendance, hospitalization, ICU admission, ventilation, AD flares (exacerbations) and persistent COVID-19 symptoms. Compared with patients on NSISS monotherapy, patients on combination treatment with or without systemic corticosteroids had significantly higher odds of hospitalization, after adjusting for confounding variables (aOR 45.75 [95%CI 4.54–616.22]) and (aOR 37.57 [95%CI 1.05–871.11]) respectively. The numbers of patients receiving combination systemic therapy was small, reflected in wide confidence intervals, and further research is warranted to validate these findings in a larger sample.

Risk of COVID-19 in patients treated with combination systemic therapy has previously been evaluated in...
THE EFFECTS OF SYSTEMIC IMMUNOMODULATORY TREATMENTS ON COVID-19 OUTCOMES IN PATIENTS WITH ATOPIC DERMATITIS: RESULTS FROM THE GLOBAL SECURE-AD REGISTRY

In a pooled analysis of 6077 patients with IMIDs (IBD, inflammatory arthritis, psoriasis) and COVID-19, TNFi in combination with thiopurines (azathioprine/6-mercaptopurine) was associated with significantly higher odds of hospitalization or death compared with TNFi monotherapy (aOR 1.74 [95%CI 1.17–2.58]), whereas TNFi combined with methotrexate was not associated with significantly higher odds of severe COVID-19 (defined as hospitalization or death) (aOR 1.18 [95%CI 0.85–1.63]). Interestingly, the use of both methotrexate and thiopurines as monotherapy was associated with higher odds of severe COVID-19 than TNFi monotherapy, highlighting the importance of evaluating the risks of specific combinations of treatments. This study adjusted for systemic corticosteroid use, rather than analysing systemic therapy in combination with corticosteroid use and found a dose-dependent relationship with corticosteroid use (aOR per 1 mg increase prednisolone-equivalent, 1.07 [95%CI 1.05–1.08]). While systemic corticosteroids are sometimes used in severe or refractory AD, they are immunosuppressive and can cause hyperglycaemia, a strong risk factor for severe COVID-19 and mortality, independent of pre-morbid diabetic status. In contrast to poorer outcomes in those on systemic corticosteroids prior to contracting COVID-19, patients on systemic corticosteroids had a lower risk of hospitalization or death compared with TNFi monotherapy (aOR 0.75 [95%CI 0.56–0.99]).

**FIGURE 3** Barchart demonstrating the proportions of patients and their pre-specified COVID-19 outcomes, according to systemic treatment groups. Patients receiving topical therapy (n = 131) were excluded to allow comparison of single agent vs combination systemic therapy for atopic dermatitis. 95% confidence intervals around the percentage of each outcome were calculated using the Pearson–Klopper method. *p*-values were calculated using Fisher’s exact test for differences across all groups (boxed *p*-values). Asterix notation identifies statistically significant differences between bracketed pairs of treatments (*p*-values >0.1 are not shown but are available in Table S4). AD, atopic dermatitis; ICU, intensive care unit; NSISS, non-steroidal immunosuppressive systemic treatment.
COVID-19, the RECOVERY trial demonstrated that dexamethasone significantly improves survival in hospitalized patients with severe COVID-19 requiring supplemental oxygen or ventilation.\textsuperscript{41} The benefit was not seen across all COVID-19 severity strata, and in hospitalized patients not requiring supplemental oxygen, dexamethasone was associated with numerically higher rates of death than usual care (17.8% vs 14.0%), although the finding was not statistically significant (rate ratio 1.19 [95%CI 0.92–1.55]). Thus, it is likely that pre-existing treatment with systemic corticosteroids increases the risk of COVID-19, whereas the hyper-inflammatory state seen in severe COVID-19 can be attenuated by systemic corticosteroids when they are administered during the course of severe illness.

Strengths and limitations

Strengths of our study include the geographically and ethnically diverse sample of patients, and a detailed description of the COVID-19 disease course in patients with AD. We included cases from 27 countries, making our findings more generalizable than single-centre, regional or national studies. Utilization of physician-reported data on AD treatments and comorbidity status reinforce the validity of the SECURE-AD data.

Our data are drawn from mostly secondary and tertiary care dermatology centres, and the sample is mostly adults. Therefore, this cohort is unlikely to be representative of the whole population of people with AD, the majority of whom are children and at overall lower risk of severe COVID-19. Thus, our conclusions should only be applied in the appropriate context.

Our study also has weaknesses. An important limitation is the absence of vaccination status of the included patients. We considered utilizing a binary timepoint cutoff, to identify patients, before and after which time, were likely to have received COVID-19 vaccination. A significant limitation of this approach would be the multitude of approaches to vaccination prioritization, provision/administration and up-take across different jurisdictions, and we felt that there was no accurate way to define a binary timepoint for such a sensitivity analysis. However, one aspect of our analysis which reassures us of the validity of our findings, despite inability to control for vaccination status, is that our adjusted analysis controlled for age, sex, BMI and comorbidity status, which in many jurisdictions, were the variables used to prioritize patients for vaccination. Therefore, it is likely that we have already (at least partially) adjusted for likelihood of vaccination by proxy, in our adjusted analysis.

A further limitation is the selection bias inherent in registry studies. Physicians may be more likely to report patients on systemic therapy, or with more severe COVID-19 infections. The absence of any reported deaths is therefore reassuring. Patients receiving systemic immunomodulatory medications may be more likely to access testing, report COVID-19 to their clinician, or come to the attention of SECURE-AD collaborating clinicians whilst hospitalized due to perceived risks associated with immunomodulation.

Because of the relatively small numbers of patients on some individual treatments, some analyses were at aggregate level. This is particularly important when interpreting findings from the combination therapy analysis, where numbers are small and the groups contain a variety of combination treatments. Data collection is ongoing and larger patient numbers will provide more power to detect differences in COVID-19 outcomes between immunomodulatory treatments. Although we have adjusted for variables such as age, gender, comorbidities and BMI, unmeasured confounding remains a possibility. Despite our global sample, numbers of patients from individual countries varied widely (median $n = 4$, range 1–139). With infrequent hospitalization, and in some countries no hospitalizations, we were thus unable to adjust for country-level differences in hospitalization rates, or country-level factors such as socioeconomic factors, background rates of COVID-19 or availability and frequency of use of systemic treatments for AD. Due to the size of our cohort, we were unable to adjust for dosage of systemic immunomodulatory treatments, including corticosteroids, or changes in the management of COVID-19 over the course of the pandemic, including vaccination.

Future perspectives

As the global COVID-19 pandemic goes on, we continue to collect data to investigate the determinants of COVID-19 outcomes in patients with AD using our web-based
SECURE-AD registry. To help us better understand the effects on patients with AD, we set up a second self-report registry platform, the SECURE-AD Patient Registry, launched globally in June 2020. Co-operation with patient organizations and the involvement of all patients is crucial, and will support further data analyses, including the impact of COVID-19 vaccination on patients with AD. Beyond our own initiatives, we strongly advocate for collaboration with and harmonization of data across COVID-19 registries to facilitate comparative analyses to gain a broad understanding of the impact of COVID-19 on patients treated with various immunomodulatory therapies. Consensus on harmonization has been reached among the leaders of the COVID-19 dermatology registries. Collaboration between registries, including non-dermatological diseases, has been crucial for the rapid generation of knowledge and can serve as an example for the prospective harmonization of data collection in the future.

CONCLUSIONS

The overall risk of COVID-19 complications appears to be low in patients with AD treated with immunomodulatory treatments. Compared with topical treatment, patients on dupilumab monotherapy were less likely to be hospitalized. Systemic monotherapy with either dupilumab or methotrexate was associated with similar odds of hospitalization. An increased rate of hospitalization was seen in patients treated with combination systemic therapy, particularly patients treated with combinations including systemic corticosteroids. Risks and benefits need to be considered by physicians who treat patients with AD using systemic therapies. We will examine the risk associated with individual immunomodulatory treatments in more detail in future analyses.

ACKNOWLEDGEMENTS

We are very grateful to all healthcare professionals who have reported cases to the SECURE-AD Physician Registry. We would also like to acknowledge our partner organizations and related registries who supported or promoted the SECURE-AD registry. We are particularly grateful to the following:

- Members of the SECURE-AD International Scientific Advisory Committee: Sebastien Barbarot MD PhD, Esther Freeman MD PhD, Emma Guttman MD PhD, USA (IEC), Jo Lambert MD PhD, Tamar Nijsten MD PhD, Amy Paller MD, Carle Paul MD PhD, Alain Taieb MD PhD, Andreas Wollenberg MD PhD, Christian Vestergaard MD PhD, Andrea Chiricozzi MD, Ketty Peris MD;
- All healthcare professionals who have submitted one or more cases in the SECURE-AD registry: Eleni Anthony, Valeria Aoki, Esther Baldrich, Alberto Barea, Paula Beattie, Anthony Bewley, Andrew Blauvelt, Andrea Carugno, Cécile Morice, Petra Cetkovska, Aisling Clery, Katerina Damesksa, Vincent Descamps, Jitske Dijkstra, Roni Dodsiuk, Marta Elosua-González, Felicity Ferguson, Susannah George, Tina Haase, Mariana Hernandez Flores, Ai Shuen Hew, Philipp Hinteregger, Manrip Hunjan, Jing Husaini, Ariënnia Hysen, Karina Jackson, Erin Kamp, Jasbinder Kaur, Dimitra Kirtisi, Emek Kocaturk, Sinead Langan, Yael Leshem, Peter Lio, Clodagh Loftus, Paula Luna, Teena Mackenzie, Satveer Mahil, Alexander Marsland, Valeria Mateeva, Zeljko Mijuskovic, Nicola Milanesi, Lucy Moorhead, Esra Musbah, John Newsham, Jane O’Connor, Swetlina Pradhan, Amy Paller, Bibiana Pérez García, Anke Piekar, Nadia Raison-Peyron, Giulia Rech, Pawinee Rerknimitr, Rosalind Simpson, Sahana Srinivas, Katarzyna Stankiewicz-Sojka, Ting Seng Tang, Efstratios Vakirlis, Richard Weller, Richard Woolf, Zenas Yiu;
- Our partner organizations: British Association of Dermatologists (BAD), European Society for Dermatological Research (ESDR), International League of Dermatological Societies (ILDS), European Task Force on Atopic Dermatitis (ETFAD), International Eczema Council (IEC), Skin Inflammation & Psoriasis International Network (SPIN), European Dermato-Epidemiology Network (EDEN), European Academy of Dermatology and Venereology (EADV), International Society of Atopic Dermatitis (ISAD), TREatment of ATopic eczema (TREAT) Registry Taskforce, TREatment of ATopic eczema – The Netherlands (TREAT NL) Registry, The UK-Irish Atopic Eczema Systemic Therapy Register (A-STAR), Nederlandse Vereniging voor Dermatologie en Venereologie (NVDV), Japanese Dermatological Association (JDA), National Eczema Association (NES);
- National and International Skin Registry Solutions (NISR) CLG for their support and expertise which enabled rapid development, deployment and maintenance of the registry platform and harmonization effort;
- The related COVID-registries: SECURE-AD Patient Survey, AAD COVID-19 registry, DA-COVID-19 registry, SECURE-Alopecia, PsoProtect, SECURE-Psoriasis, SECURE-IBD, COVID-19 Global Rheumatology Alliance.

FUNDING INFORMATION

The SECURE-AD register is supported through a grant for skin disease registries held by Alan Irvine (National and International Skin Registries; NISR) as well as the National Institute for Health Research Biomedical Research Centre at Guy’s & St Thomas’ NHS Foundation Trust and King’s College London as well as by research funding of the Department of Dermatology, University of Amsterdam.

CONFLICT OF INTEREST

A.H. Musters: None. C. Broderick received support for attending meetings and/or travel from Abbvie (Attendance at British Association of Dermatologists annual meeting 2021). D. Prieto-Merino: None. A. Chiricozzi received consulting fees from Abbvie, Almirall, Biogen, Fresenius Kabi, Leo Pharma, Lilly, Janssen, Novartis, Sanofi Genzyme and UCB Pharma; Payment or honoraria for lectures, presentations,
speakers bureaus, manuscript writing or educational events from AbbVie, Almirall, Leo Pharma, Lilly, Janssen, Novartis, and Sanofi Genzyme. G. Damiani: None. K. Peris: None. S. Dhar: None. A. De: None. E. Freeman: Royalties UpToDate: COVID-19 Dermatology Author; Other financial or non-financial interests: Member of American Academy COVID-19 Task Force (unpaid). B.W.M. Arents: None. T. Burton: None. A.L. Bosma: None. C.-C. Chi: None. G. Fletcher: None. A.M. Drucker: None. K. Kabashima received grants or contracts form Japan tobacco Inc., Kao, LEO Pharma, Chugai Pharmaceutical, Maruho, Pola Pharma, Abbvie, Eli Lilly, Sanofi, and Pfizer, Kose, and Kyorin Pharmaceutical; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from LEO Pharma, Japan tobacco Inc., P&G Japan, Eli Lilly Japan, Tanabe Mitsubishi, Ono Pharmaceutical, Kyowa Kirin, Pola Pharma, AbbVie, and Sanofi. E.F. de Monchy: None. M. Panda: None. D. Wall is employed (as an Health Informatician) by National and International Skin Registry Solutions (NISR), a charity limited by guarantee, that develops national and international patient registries; NISR provided funding to support the development of the SECURE-AD platform and resources required to launch and maintain the project. He provided expertise specifically regarding this; consultancy fees from Eli Lilly and Company; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Fondation Rene Touraine; Support for attending meetings and/or travel from Pfizer and Janssen (To attend virtual British Association of Dermatologists meeting 2020/2021). C. Vestergaard received consulting fees from AbbVie, Almirall, Leo Pharma, Eli Lilly, Novartis, Sanofi Genzyme; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Almirall, Leo Pharma, Lilly, Novartis, and Sanofi Genzyme. E. Mahé received grants or contracts from Sanofi and Abbvie; Consulting fees from Sanofi and Abbvie. L. Bonzano: None. L. Kattach received consulting fees from AbbVie; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events; Support for attending meetings and/or travel from Lilly to attend the BNDG and BAD conferences. M. Napolitano received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. M.F. Ordoñez-Rubiano received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Sanofi, Abbvie and Leo Pharma. E. Haufe: None. C. Patruno received consulting fees from AbbVie, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi, and Leo Pharma; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi, and Leo Pharma. A.D. Irvine received consulting fees from Arena, Amirall, Pfizer, Regenron, Sanofi, Novarti, Abbvie, Benevolent Ai, and Lilly; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Leo, Abbvie, Lilly, and Sanofi; Participation on a Data Safety Monitoring Board or Advisory Board for Novartis (paid); Leadership or fiduciary role in other board, society, committee or advocacy group at International Eczema Council (unpaid) and Irish Hospital Consultants Association (unpaid). P.I. Spuls has done consultancies in the past for Sanofi 111,017 and AbbVie 041217 (unpaid), received a department independent research grants for TREAT NL registry from Pharma since December 2019, is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of e.g. psoriasis and atopic dermatitis, for which financial compensation is paid to the department/hospital and, is Chief Investigator (CI) of the systemic and phototherapy atopic eczema registry (TREAT NL) for adults and children and one of the main investigator of the SECURE-AD registry. C. Flohr received grants from NIHR UK/EU Horizon 2020 (TREAT and SOFTER trial/ BIOMAP and Trans-Foods consortia (CI/PI), Sanofi (Investigator-led microbiome research programme) and Pfizer (Investigator-led microbiome research programme)).

DATA AVAILABILITY STATEMENT
Please contact the corresponding author with any requests.

ORCID
Annelie H. Musters https://orcid.org/0000-0002-6209-4554
Conor Broderick https://orcid.org/0000-0002-3588-5000
Ketty Peris https://orcid.org/0000-0003-1957-6600
Esther Freeman https://orcid.org/0000-0001-7751-9466
Angela Leigh-Ann L. Bosma https://orcid.org/0000-0001-6807-6042
Aaron M. Drucker https://orcid.org/0000-0002-7388-9475
Maitreyee Panda https://orcid.org/0000-0002-2919-2953
Christian Vestergaard https://orcid.org/0000-0001-6485-3158
Emmanuel Mahé https://orcid.org/0000-0001-5780-1827
Laura Bonzano https://orcid.org/0000-0002-8933-4626
Maddalena Napolitano https://orcid.org/0000-0003-3309-8190
Carsten Flohr https://orcid.org/0000-0003-4884-6286

REFERENCES
1. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021;93:1449–58.
2. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–6.
3. Langan SM, Alan ID, Weidinger S. Atopic dermatitis. Allergy. 2014;69:3–16.
4. Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014;69:3–16.
5. Droitcourt C, Vittrup I, Kerbrat S, Egeberg A, Thyssen JP. Risk of systemic infections in adults with atopic dermatitis: a nationwide cohort study. J Am Acad Dermatol. 2021;84:290–9.
6. Patrick MT, Zhang H, Wasikowski R, Prens EP, Weidinger S, Godsonen JE, et al. Associations between COVID-19 and skin...
THE EFFECTS OF SYSTEMIC IMMUNOMODULATORY TREATMENTS ON COVID-19 OUTCOMES IN PATIENTS WITH ATOPIC DERMATITIS: RESULTS FROM THE GLOBAL SECURE-AD REGISTRY

1. Beck LA, Thaçi D, Deleuran M, Blauvelt A, Bissonnette R, de Vroen A, et al. Effects of systemic immunosuppressive therapies for moderate-to-severe eczema in children and adults. Cochrane Database Syst Rev. 2018;2018:CD011939.

2. Schmitt J, Schäkel K, Schmitt N, Meurer M. Systemic treatment of severe atopic eczema: a systematic review. Acta Dermato-Venereologica. 2007;87(2):100–11.

3. Roeevi F, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol. 2014;133:429–38.

4. Dommasch ED, Kim SC, Lee MP, Gagne JJ. Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis. JAMA Dermatol. 2019;155:1142.

5. Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ. Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;18:69–81.e63.

6. Beck LA, Thaçi D, Deleuran M, Bluettet A, Bissonnette R, de Vroen A, et al. Dupilumab provides safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2020;82:567–77.

7. Yiou ZZN, Ashcroft DM, Evans J, McElhone K, Lunt M, Smith CH, et al. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the UK and Republic of Ireland: results from the British Association of Dermatologists biologic interventions register (BADBIR). Br J Dermatol. 2019;180:329–37.

8. Chiricozzi A, Talamonti M, De Simone C, Galluzzo M, Gori N, Fabbrocini G, et al. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry. Allergy. 2021;76:1813–24.

9. Wu JJ, Martin A, Liu J, Thaitiparthi A, Ge S, Egberg A, et al. The risk of COVID-19 infection in patients with atopic dermatitis: a retrospective cohort study. J Am Acad Dermatol. 2022;86:243–5.

10. Ungar B, Glickman JW, Golant AK, Dubin C, Marushchak O, Gontzes A, et al. COVID-19 symptoms are attenuated in moderate-to-severe COVID-19: a suitable treatment? Lancet Infect Dis. 2020;20:1202–3.

11. Bronte V, Ugol S, Tinazzi E, Vella A, De Sanctis F, Cane S, et al. Baricitinib renews the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020;130:409–16.

12. Titian BK, Farley MM, Melha A, Connor-Schnitzler R, Moanna A, Cribbs SK, et al. Use of Baricitinib in patients with moderate to severe COVID-19: a single-center real-life experience. Dermatol Ther. 2020;33:e13765.

13. Napolitano M, Patruno C, Ruggiero A, Nocerino M, Fabbrocini G. Safety of dupilumab in atopic patients during COVID-19 outbreak. J Dermatol Treat. 2020;1:600–1.

14. Carugno A, Raponi F, Vecchiati AL, Vezzoli P, Gambini DM, Di Mercurio M, et al. No evidence of increased risk for Coronavirus Disease 2019 (COVID-19) in patients treated with Dupilumab for atopic dermatitis in a high - epidemic area – Bergamo, Lombardy, Italy. J Eur Acad Dermatol Venereol. 2020;34:e433–4.

15. Patruno C, Stingeni L, Fabbrocini G, Hansel K, Napolitano M. Dupilumab and COVID-19: what should we expect? Dermatol Therapy. 2020;33:e13502.

16. Izadi Z, Brenner B, Mahik SK, Dand N, Yiou ZZN, Yates M, et al. Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open. 2021;4:e2129639.

17. Carrasco-Sánchez FJ, López-Carmona MD, Martinez-Marcos FJ, Pérez-Belmonte LM, Hidalgo-Jiménez A, Buonaiuto V, et al. Admission hyperglycaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: data from the Spanish SEMI-COVID-19 registry. Ann Med. 2021;53:103–16.

18. Horby P, Lim WS, Emberson JR, Mahfam M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704.

19. Wall D, Alhusayen R, Arens B, Apfelbacher C, Balogh EA, Bokhari L, et al. Learning from disease registries during a pandemic.
moving toward an international federation of patient registries. Clin Dermatol. 2021;39:467–78.

43. Freeman EE, McMahon DE, Hruza GJ, Irvine AD, Spuls PI, Smith CH, et al. International collaboration and rapid harmonization across dermatologic COVID-19 registries. J Am Acad Dermatol. 2020;83:e261–6.

44. Freeman EE, Chamberlin GC, McMahon DE, Hruza GJ, Wall D, Meah N, et al. Dermatology COVID-19 registries: updates and future directions. Dermatol Clin. 2021;39:575–85.

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Musters AH, Broderick C, Prieto-Merino D, Chiricozzi A, Damiani G, Peris K, et al. The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registry. J Eur Acad Dermatol Venereol. 2023;37:365–381. https://doi.org/10.1111/jdv.18613